{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:34:48Z","timestamp":1790303688013,"version":"4.1.0"},"reference-count":185,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.apsb.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T04:36:43Z","timestamp":1654922203000},"page":"4040-4055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs\u2014Therapeutic potential exploration in lung injury"],"prefix":"10.1016","volume":"12","author":[{"given":"Juan","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Nuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0307-7391","authenticated-orcid":false,"given":"Tianru","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2022.06.003_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metabol"},{"key":"10.1016\/j.apsb.2022.06.003_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2019.00260","article-title":"From the incretin concept and the discovery of GLP-1 to today's diabetes therapy","volume":"10","author":"Holst","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.apsb.2022.06.003_bib3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/edrv.20.6.0385","article-title":"The glucagon-like peptides","volume":"20","author":"Kieffer","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2022.06.003_bib4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabol"},{"key":"10.1016\/j.apsb.2022.06.003_bib5","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.06.003_bib6","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","article-title":"Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.06.003_bib7","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.06.003_bib8","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00069.2016","article-title":"Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives","volume":"311","author":"Jin","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.apsb.2022.06.003_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4158\/EP.13.5.444","article-title":"Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin","volume":"13","author":"Viswanathan","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.apsb.2022.06.003_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2017.07.015","article-title":"Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds","volume":"812","author":"Insuela","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2022.06.003_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metabol"},{"issue":"Suppl 1","key":"10.1016\/j.apsb.2022.06.003_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.apsb.2022.06.003_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.06.003_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2018.09.011","article-title":"Incretin drugs as modulators of atherosclerosis","volume":"278","author":"Gallego-Colon","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2022.06.003_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.apsb.2022.06.003_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2022.06.003_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-014-0198-2","article-title":"Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.apsb.2022.06.003_bib19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.06.003_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00257346","article-title":"Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption","volume":"24","author":"Ebert","year":"1983","journal-title":"Diabetologia"},{"key":"10.1016\/j.apsb.2022.06.003_bib21","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1016\/S0021-9258(18)32858-8","article-title":"Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA","volume":"258","author":"Lund","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.003_bib22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.06.003_bib23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1210\/endo-119-4-1467","article-title":"Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas","volume":"119","author":"Orskov","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib24","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/nar\/14.12.4719","article-title":"Structure of the human glucagon gene","volume":"14","author":"White","year":"1986","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2022.06.003_bib25","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1210\/endo-115-6-2176","article-title":"Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid","volume":"115","author":"Heinrich","year":"1984","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib26","doi-asserted-by":"crossref","first-page":"14082","DOI":"10.1016\/S0021-9258(18)89859-3","article-title":"Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon","volume":"259","author":"Heinrich","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.003_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(00)00232-9","article-title":"Molecular evolution of proglucagon","volume":"98","author":"Irwin","year":"2001","journal-title":"Regul Pept"},{"key":"10.1016\/j.apsb.2022.06.003_bib28","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1016\/S0021-9258(18)68261-4","article-title":"Glucagon gene expression in vertebrate brain","volume":"263","author":"Drucker","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.003_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrendo.2015.51","article-title":"Islet \u03b1 cells and glucagon\u2014critical regulators of energy homeostasis","volume":"11","author":"Campbell","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/JOE-12-0368","article-title":"Unraveling oxyntomodulin, GLP1's enigmatic brother","volume":"215","author":"Pocai","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellsig.2009.09.032","article-title":"New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1)","volume":"22","author":"Yu","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2022.06.003_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4161\/isl.23345","article-title":"New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic beta-cells: the involvement of the Wnt signaling pathway effector beta-catenin","volume":"4","author":"Xiong","year":"2012","journal-title":"Islets"},{"key":"10.1016\/j.apsb.2022.06.003_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/JOE-08-0085","article-title":"Mechanisms underlying proglucagon gene expression","volume":"198","author":"Jin","year":"2008","journal-title":"J Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2337\/diab.42.5.658","article-title":"Biological effects and metabolic rates of glucagonlike peptide-1 7\u201336 amide and glucagonlike peptide-1 7\u201337 in healthy subjects are indistinguishable","volume":"42","author":"Orskov","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib35","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.06.003_bib36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2337\/diab.38.3.338","article-title":"Glucagonlike peptide I (7\u201337) actions on endocrine pancreas","volume":"38","author":"Weir","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7\u201337) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.06.003_bib38","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51 Suppl 3","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib39","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.06.003_bib40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/diab.37.2.200","article-title":"Incretin effect due to increased secretion and decreased clearance of insulin in normal humans","volume":"37","author":"Shuster","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170213","article-title":"The role of GIP in alpha-cells and glucagon secretion","volume":"125","author":"El","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2022.06.003_bib43","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib44","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in\u00a0vitro and in\u00a0vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib45","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib46","doi-asserted-by":"crossref","first-page":"E1348","DOI":"10.1152\/ajpendo.00376.2013","article-title":"GLP-1-derived nonapeptide GLP-1(28\u201336)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice","volume":"305","author":"Ip","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib47","doi-asserted-by":"crossref","first-page":"E1263","DOI":"10.1152\/ajpendo.00600.2012","article-title":"GLP-1(28\u201336) improves beta-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP\/PKA\/beta-catenin signaling in beta-cells in vitro","volume":"304","author":"Shao","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib48","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2337\/db14-1708","article-title":"GLP-1(32\u201336)amide pentapeptide increases basal energy expenditure and inhibits weight gain in obese mice","volume":"64","author":"Tomas","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib49","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.06.003_bib50","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.coph.2013.08.013","article-title":"Molecular mechanisms of incretin hormone secretion","volume":"13","author":"Ezcurra","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.apsb.2022.06.003_bib51","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/1753-0407.12439","article-title":"The incretin hormone GLP-1 and mechanisms underlying its secretion","volume":"8","author":"Tian","year":"2016","journal-title":"J Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12986-016-0153-3","article-title":"Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review","volume":"13","author":"Bodnaruc","year":"2016","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.apsb.2022.06.003_bib53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/me.2015-1306","article-title":"GPR119 agonist AS1269574 activates TRPA1 cation channels to stimulate GLP-1 secretion","volume":"30","author":"Chepurny","year":"2016","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib54","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/db13-0903","article-title":"Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway","volume":"63","author":"Nguyen","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib56","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.2513","article-title":"Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells","volume":"17","author":"Ellingsgaard","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib57","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.2337\/db14-0100","article-title":"GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering","volume":"63","author":"Kahles","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib58","doi-asserted-by":"crossref","first-page":"bnaa011","DOI":"10.1210\/endrev\/bnaa011","article-title":"Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications","volume":"41","author":"Drucker","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2022.06.003_bib59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12933-016-0330-8","article-title":"Interleukin-6 predicts inflammation-induced increase of glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism","volume":"15","author":"Lebherz","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.apsb.2022.06.003_bib60","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bbmt.2019.01.036","article-title":"Glucagon-like peptide-1 is a marker of systemic inflammation in patients treated with high-dose chemotherapy and autologous stem cell transplantation","volume":"25","author":"Ebbesen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.apsb.2022.06.003_bib61","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.surg.2020.01.004","article-title":"Plasma glucagon-like peptide 1 was associated with hospital-acquired infections and long-term mortality in burn patients","volume":"167","author":"Yin","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/j.apsb.2022.06.003_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2982","article-title":"Sepsis-induced activation of endogenous GLP-1 system is enhanced in type 2 diabetes","volume":"34","author":"Perl","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.apsb.2022.06.003_bib63","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.003_bib64","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1074\/jbc.272.7.4108","article-title":"Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard","volume":"272","author":"Chen","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.003_bib65","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrd1828","article-title":"Exenatide","volume":"4","author":"Davidson","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.06.003_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.apsb.2022.06.003_bib67","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.apsb.2022.06.003_bib68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/13543784.2011.562191","article-title":"Lixisenatide for type 2 diabetes mellitus","volume":"20","author":"Christensen","year":"2011","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.apsb.2022.06.003_bib69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","article-title":"Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes","volume":"51","author":"Juhl","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib70","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","article-title":"Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes","volume":"30","author":"Vilsb\u00f8ll","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.apsb.2022.06.003_bib71","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.06.003_bib72","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2022.06.003_bib73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S2213-8587(17)30012-8","article-title":"Semaglutide: a promising new glucagon-like peptide-1 receptor agonist","volume":"5","author":"Scheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib74","doi-asserted-by":"crossref","first-page":"Jc29","DOI":"10.7326\/ACPJ201909170-029","article-title":"In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c","volume":"171","author":"Lipscombe","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib75","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahr\u00e9n","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154295","article-title":"The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes","volume":"109","author":"Stoian","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.apsb.2022.06.003_bib77","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00592-018-1222-z","article-title":"The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials","volume":"56","author":"Ling","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.apsb.2022.06.003_bib78","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.apsb.2022.06.003_bib79","doi-asserted-by":"crossref","first-page":"L834","DOI":"10.1152\/ajplung.00031.2018","article-title":"DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice","volume":"315","author":"Kawasaki","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.apsb.2022.06.003_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.731453","article-title":"The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2022.06.003_bib81","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41419-021-04227-0","article-title":"Sitagliptin activates the p62\u2013Keap1\u2013Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury","volume":"12","author":"Kong","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2022.06.003_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.apsb.2022.06.003_bib83","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/dme.12301","article-title":"The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits","volume":"30","author":"Ryder","year":"2013","journal-title":"Diabet Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib84","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.apsb.2022.06.003_bib85","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagon-like peptide-1 receptor agonists\u2014available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.apsb.2022.06.003_bib86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1573399812666151223093841","article-title":"Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy","volume":"12","author":"Drab","year":"2016","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.apsb.2022.06.003_bib87","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/dia.2010.0048","article-title":"Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus","volume":"13","author":"Wu","year":"2011","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.apsb.2022.06.003_bib89","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.apsb.2022.06.003_bib90","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib91","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/phar.1301","article-title":"Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial","volume":"33","author":"Derosa","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.apsb.2022.06.003_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97967-0","article-title":"Effect of liraglutide on expression of inflammatory genes in type 2 diabetes","volume":"11","author":"Zobel","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.06.003_bib93","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/en.2007-0358","article-title":"Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells","volume":"148","author":"Sherry","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib94","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","article-title":"Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency","volume":"1150","author":"Xue","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.apsb.2022.06.003_bib95","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","article-title":"Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells","volume":"53","author":"Hadjiyanni","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.apsb.2022.06.003_bib96","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3390\/ijms20071584","article-title":"Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system","volume":"20","author":"Chiou","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.06.003_bib97","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2337\/db09-1618","article-title":"Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways","volume":"59","author":"Kim","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib98","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12020-019-02081-x","article-title":"Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice","volume":"66","author":"Sha","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.apsb.2022.06.003_bib99","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.2337\/db16-0317","article-title":"DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1\/M2 macrophage polarization","volume":"65","author":"Zhuge","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/JIR.S84993","article-title":"Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia","volume":"8","author":"Yanay","year":"2015","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.apsb.2022.06.003_bib101","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165826","article-title":"Glucagon-like peptide 1 improves insulin resistance in\u00a0vitro through anti-inflammation of macrophages","volume":"49","author":"Guo","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.apsb.2022.06.003_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105969","article-title":"Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages","volume":"77","author":"Lu","year":"2019","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.apsb.2022.06.003_bib103","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1152\/ajpendo.00553.2014","article-title":"DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-\u03baB activation","volume":"309","author":"Shinjo","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib104","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/hep.31856","article-title":"Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge","volume":"74","author":"Liu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2022.06.003_bib105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/en.2012-1937","article-title":"GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE\u2013\/\u2013 mice","volume":"154","author":"Panjwani","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib106","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib107","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in\u00a0vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2022.06.003_bib108","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41467-020-14384-z","article-title":"Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase","volume":"11","author":"Byun","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.06.003_bib109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib110","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","article-title":"Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1","volume":"89","author":"Thorens","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.06.003_bib111","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib112","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/endo.134.5.8156917","article-title":"Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse","volume":"134","author":"Campos","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib113","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2022.06.003_bib114","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib115","doi-asserted-by":"crossref","first-page":"bqaa201","DOI":"10.1210\/endocr\/bqaa201","article-title":"GLP-1 receptor signaling differentially modifies the outcomes of sterile vs viral pulmonary inflammation in male mice","volume":"161","author":"Sato","year":"2020","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000370","article-title":"Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis","volume":"7","author":"Yokomori","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.apsb.2022.06.003_bib117","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4093\/dmj.2012.36.4.262","article-title":"GLP-1 receptor agonist and non-alcoholic fatty liver disease","volume":"36","author":"Lee","year":"2012","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.apsb.2022.06.003_bib118","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib119","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/en.2017-00812","article-title":"Characterization of the glucagonlike peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization","volume":"159","author":"Jensen","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5551\/jat.43414","article-title":"GLP-1 receptor agonist exendin-4 attenuates NR4A orphan nuclear receptor NOR1 expression in vascular smooth muscle cells","volume":"26","author":"Takahashi","year":"2019","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.apsb.2022.06.003_bib121","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3892\/mmr.2017.6618","article-title":"Overexpression of GLP-1 receptors suppresses proliferation and cytokine release by airway smooth muscle cells of patients with chronic obstructive pulmonary disease via activation of ABCA1","volume":"16","author":"Sun","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2022.06.003_bib122","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1152\/ajpendo.00292.2020","article-title":"Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein","volume":"319","author":"Zhou","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib123","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153732","article-title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","volume":"6","author":"McLean","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2022.06.003_bib124","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","article-title":"Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists","volume":"203","author":"Foer","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cea.12860","article-title":"Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation","volume":"47","author":"Mitchell","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.apsb.2022.06.003_bib126","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fimmu.2019.00364","article-title":"IL33: roles in allergic inflammation and therapeutic perspectives","volume":"10","author":"Chan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2022.06.003_bib127","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S2213-2600(19)30055-4","article-title":"Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies","volume":"7","author":"Pividori","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib128","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1038\/s41467-021-26347-z","article-title":"Asthma-associated genetic variants induce IL33 differential expression through an enhancer-blocking regulatory region","volume":"12","author":"Aneas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.06.003_bib129","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2017.11.043","article-title":"Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo","volume":"142","author":"Toki","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2022.06.003_bib130","doi-asserted-by":"crossref","first-page":"20195","DOI":"10.3390\/ijms160920195","article-title":"Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-\u03baB (NF-\u03baB) signaling pathway in mice","volume":"16","author":"Zhu","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.06.003_bib131","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/crj.13372","article-title":"Use of GLP1RAs and occurrence of respiratory disorders: a meta-analysis of large randomized trials of GLP1RAs","volume":"15","author":"Wei","year":"2021","journal-title":"Clin Respir J"},{"key":"10.1016\/j.apsb.2022.06.003_bib132","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.2147\/COPD.S175145","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients","volume":"13","author":"Huang","year":"2018","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.apsb.2022.06.003_bib133","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.apsb.2022.06.003_bib134","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1164\/ajrccm.163.4.9912132","article-title":"Glucagon-like peptide-1(7\u201336) amide stimulates surfactant secretion in human type II pneumocytes","volume":"163","author":"Vara","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib135","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1165\/ajrcmb.26.1.4652","article-title":"Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology","volume":"26","author":"Vernooy","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.apsb.2022.06.003_bib136","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0091-6749(97)70253-7","article-title":"A new murine model of pulmonary eosinophilic hypersensitivity: contribution to experimental asthma","volume":"100","author":"de Siqueira","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2022.06.003_bib137","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1210\/en.2013-1666","article-title":"Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice","volume":"154","author":"Viby","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib138","first-page":"L645","article-title":"C-type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats","volume":"275","author":"Klinger","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.apsb.2022.06.003_bib139","doi-asserted-by":"crossref","first-page":"bvz034","DOI":"10.1210\/jendso\/bvz034","article-title":"Glucagon-like peptide 1 and atrial natriuretic peptide in a female mouse model of obstructive pulmonary disease","volume":"4","author":"Balk-Moller","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.apsb.2022.06.003_bib140","first-page":"L374","article-title":"GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery","volume":"265","author":"Richter","year":"1993","journal-title":"Am J Physiol"},{"key":"10.1016\/j.apsb.2022.06.003_bib141","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1465-9921-14-82","article-title":"Pyocyanin-induced mucin production is associated with redox modification of FOXA2","volume":"14","author":"Hao","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.apsb.2022.06.003_bib142","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41385-020-0262-1","article-title":"Exendin-4 restores airway mucus homeostasis through the GLP1R\u2013PKA\u2013PPARgamma\u2013FOXA2\u2013phosphatase signaling","volume":"13","author":"Choi","year":"2020","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.apsb.2022.06.003_bib143","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.4049\/jimmunol.180.11.7664","article-title":"Acute lung injury induced by lipopolysaccharide is independent of complement activation","volume":"180","author":"Rittirsch","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2022.06.003_bib144","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s11095-010-0322-4","article-title":"A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles","volume":"28","author":"Lim","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2022.06.003_bib145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.nano.2016.08.004","article-title":"GLP-1 nanomedicine alleviates gut inflammation","volume":"13","author":"Anbazhagan","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2022.06.003_bib146","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1210\/en.2012-1786","article-title":"Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats","volume":"154","author":"Roman\u00ed-P\u00e9rez","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib147","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3601454","article-title":"GLP-1 analogue liraglutide enhances SP-A expression in LPS-induced acute lung injury through the TTF-1 signaling pathway","volume":"2018","author":"Zhu","year":"2018","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.apsb.2022.06.003_bib148","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41374-018-0170-0","article-title":"Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function","volume":"99","author":"Xu","year":"2019","journal-title":"Lab Invest"},{"key":"10.1016\/j.apsb.2022.06.003_bib149","article-title":"Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS\/sGC\/PKG pathways","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.06.003_bib150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0167-0115(01)00300-7","article-title":"Vasorelaxant effect of glucagon-like peptide-(7\u201336)amide and amylin on the pulmonary circulation of the rat","volume":"102","author":"Golpon","year":"2001","journal-title":"Regul Pept"},{"key":"10.1016\/j.apsb.2022.06.003_bib151","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2014.07.010","article-title":"Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-kappaB in mice","volume":"22","author":"Gou","year":"2014","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.apsb.2022.06.003_bib152","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.apsb.2020.05.006","article-title":"Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment","volume":"10","author":"Jin","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2022.06.003_bib153","article-title":"Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment","volume":"22","author":"Pang","year":"2021","journal-title":"Obes Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib154","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.1184003","article-title":"The NLRP3 inflammasome: a sensor for metabolic danger?.","volume":"327","author":"Schroder","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.06.003_bib155","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1210\/me.2014-1095","article-title":"Minireview: thioredoxin-interacting protein: regulation and function in the pancreatic beta-cell","volume":"28","author":"Shalev","year":"2014","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib156","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3233\/JAD-180735","article-title":"Metabolic syndrome, brain insulin resistance, and Alzheimer's disease: thioredoxin interacting protein (TXNIP) and inflammasome as core amplifiers","volume":"66","author":"Nasoohi","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.apsb.2022.06.003_bib157","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1210\/en.2004-1378","article-title":"Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis","volume":"146","author":"Minn","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib158","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cellsig.2010.04.001","article-title":"Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells","volume":"22","author":"Shao","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2022.06.003_bib159","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/JOE-20-0109","article-title":"GABA requires GLP-1R to exert its pancreatic function during STZ challenge","volume":"246","author":"Shao","year":"2020","journal-title":"J Endocrinol"},{"key":"10.1016\/j.apsb.2022.06.003_bib160","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1210\/en.2002-220564","article-title":"Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway","volume":"143","author":"Shalev","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.06.003_bib161","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MED.0000000000000391","article-title":"Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP","volume":"25","author":"Thielen","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.apsb.2022.06.003_bib162","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1073\/pnas.1432929100","article-title":"Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects","volume":"100","author":"Ortiz","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.06.003_bib163","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1097\/CCM.0000000000002833","article-title":"Mesenchymal stem cells from bone marrow, adipose tissue, and lung tissue differentially mitigate lung and distal organ damage in experimental acute respiratory distress syndrome","volume":"46","author":"Silva","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib164","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/14712590903213651","article-title":"Potential application of mesenchymal stem cells in acute lung injury","volume":"9","author":"Lee","year":"2009","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.apsb.2022.06.003_bib165","doi-asserted-by":"crossref","first-page":"17438","DOI":"10.1073\/pnas.0608249103","article-title":"Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD\/scid mice","volume":"103","author":"Lee","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.06.003_bib166","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm1391","article-title":"Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction","volume":"12","author":"Miyahara","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib167","doi-asserted-by":"crossref","first-page":"11002","DOI":"10.1073\/pnas.0704421104","article-title":"Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury","volume":"104","author":"Ortiz","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.06.003_bib168","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1540-8191.2009.00984.x","article-title":"What's new in cardiac cell therapy? Allogeneic bone marrow stromal cells as \"universal donor cells\"","volume":"25","author":"Kinkaid","year":"2010","journal-title":"J Card Surg"},{"key":"10.1016\/j.apsb.2022.06.003_bib169","doi-asserted-by":"crossref","first-page":"S569","DOI":"10.1097\/CCM.0b013e3181f1ff1d","article-title":"Mesenchymal stem cells for acute lung injury: preclinical evidence","volume":"38","author":"Matthay","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib170","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1371\/journal.pmed.0040269","article-title":"Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1","volume":"4","author":"Mei","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib171","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4049\/jimmunol.179.3.1855","article-title":"Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice","volume":"179","author":"Gupta","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2022.06.003_bib172","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/sctm.18-0038","article-title":"Concise review: therapeutic potential of the mesenchymal stem cell derived secretome and extracellular vesicles for radiation-induced lung injury: progress and hypotheses","volume":"8","author":"Xu","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib173","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13287-020-01699-3","article-title":"Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury","volume":"11","author":"Du","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2022.06.003_bib174","article-title":"Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives","volume":"2019","author":"Harrell","year":"2019","journal-title":"Stem Cell Int"},{"key":"10.1016\/j.apsb.2022.06.003_bib175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13238-020-00738-2","article-title":"Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics","volume":"11","author":"Qin","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2022.06.003_bib176","doi-asserted-by":"crossref","first-page":"E634","DOI":"10.1152\/ajpendo.00460.2009","article-title":"Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow","volume":"298","author":"Sanz","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.06.003_bib177","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5966\/sctm.2012-0064","article-title":"Encapsulated glucagon-like peptide-1-producing mesenchymal stem cells have a beneficial effect on failing pig hearts","volume":"1","author":"Wright","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.apsb.2022.06.003_bib178","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3727\/096368912X638973","article-title":"Feasibility of intracoronary GLP-1 eluting CellBead infusion in acute myocardial infarction","volume":"22","author":"Houtgraaf","year":"2013","journal-title":"Cell Transplant"},{"key":"10.1016\/j.apsb.2022.06.003_bib179","article-title":"Combined MSC and GLP-1 therapy modulates collagen remodeling and apoptosis following myocardial infarction","volume":"2016","author":"Wright","year":"2016","journal-title":"Stem Cell Int"},{"key":"10.1016\/j.apsb.2022.06.003_bib180","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13287-020-01689-5","article-title":"Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA\/beta-catenin","volume":"11","author":"Yang","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2022.06.003_bib181","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13287-019-1492-6","article-title":"Effect of hCMSCs and liraglutide combination in ALI through cAMP\/PKAc\/beta-catenin signaling pathway","volume":"11","author":"Feng","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.apsb.2022.06.003_bib182","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.003_bib183","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s13300-020-00898-8","article-title":"ACE2 and SARS-CoV-2 infection: might GLP-1 receptor agonists play a role?.","volume":"11","author":"Monda","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.apsb.2022.06.003_bib184","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12439","article-title":"Glucagon-like peptide-1 receptor agonists in the era of COVID-19: friend or foe?.","volume":"11","author":"Belancic","year":"2021","journal-title":"Clin Obes"},{"key":"10.1016\/j.apsb.2022.06.003_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109031","article-title":"Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and meta-regression","volume":"179","author":"Hariyanto","year":"2021","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522002696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522002696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:56:43Z","timestamp":1761929803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383522002696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":185,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2211383522002696"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2022.06.003","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.163913208.81687299\/v1","asserted-by":"object"}]},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs\u2014Therapeutic potential exploration in lung injury","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}